[THE INVESTOR] South Korea’s state drug safety watchdog said on Jan. 5 it has imposed a temporary ban on imports of a smoking cessation gum produced by GlaxoSmithKline for a month on charges of violating the Pharmaceutical Affairs Act.
Starting from Jan 10, GlaxoSmithKline Consumer Healthcare Korea will be banned from importing Nicotin-L Gum 2mg as the company failed to report the changes of the nicotine replacement’s manufacturer, according to the Ministry of Food and Drug Safety.
By Park Han-na (hnpark@heraldcorp.com)